Cancer Metabolism: From molecules to medicine

TL;DR

Understanding the metabolic pathways in different types of cancer is crucial for developing targeted therapies, but challenges remain in identifying the best interventions and patient selection.

Transcript

Hello. Good evening. I'm Gina Vild. I'm the chief communications officer for Harvard Medical School, and I am thrilled to welcome you here tonight. This is the 19th year that we've been offering Harvard Medical School's Mini-Med School to those in Boston, and more recently, to those throughout the world. So to all of you here in the auditorium and ... Read More

Key Insights

• ♋ Cancer cells undergo metabolic reprogramming to support their growth and survival, often utilizing different metabolic pathways compared to normal cells.
• 🥹 Targeting metabolic vulnerabilities in cancer cells holds promise for therapeutic interventions, but challenges remain in identifying the right compounds and patient populations.
• ♋ Understanding the metabolic differences between cancer types and individual patients is crucial for personalized treatments.
• 🎯 The therapeutic window between cancer cells and normal cells is a primary concern in developing targeted therapies.

Questions & Answers

Q: How do you ensure that drugs targeting metabolic pathways only affect cancer cells and not normal cells?

Selective targeting of cancer cells is challenging, but through careful study and understanding of metabolic differences between cancer and normal cells, researchers aim to identify specific vulnerabilities in cancer metabolism that can be exploited while minimizing off-target effects.

Q: What are the limitations of targeting metabolic pathways?

Metabolic reprogramming in cancer cells can be complex, and targeting specific pathways may lead to compensatory mechanisms and resistance. Additionally, the diverse metabolic features across different cancer types require tailored approaches, and the therapeutic window must be carefully considered.

Q: Are there certain types of cancers that are more likely to use glutamine in metabolism?

Different cancer types have unique metabolic preferences. Mixed signaling cancers often rely on glutamine and amino acids. However, it is essential to examine the specific genetic and metabolic characteristics of each cancer to determine fuel preferences and therapeutic targets.

Q: How do you decide which metabolic pathways to target in cancer treatment?

Identifying which metabolic pathways to target in cancer treatment depends on various factors, including the genetics of the tumor, the tumor's nutrient niche, and the patient's individual physiology and dietary intake. Personalized medicine approaches aim to match patients with the most appropriate metabolic pathway inhibitors based on these factors.

Key Insights:

• Cancer cells undergo metabolic reprogramming to support their growth and survival, often utilizing different metabolic pathways compared to normal cells.
• Targeting metabolic vulnerabilities in cancer cells holds promise for therapeutic interventions, but challenges remain in identifying the right compounds and patient populations.
• Understanding the metabolic differences between cancer types and individual patients is crucial for personalized treatments.
• The therapeutic window between cancer cells and normal cells is a primary concern in developing targeted therapies.
• Advances in genomic analysis and experimental models are expanding our understanding of cancer metabolism and guiding the development of targeted therapies.

Summary & Key Takeaways

• Cancer cells undergo metabolic reprogramming to support their growth, often using different fuel sources compared to normal cells.

• KRAS mutations play a significant role in pancreatic cancer, driving altered metabolism and nutrient utilization in the tumor.

• Targeting cancer metabolism has shown promise in preclinical and experimental models, but there are challenges in finding the right therapeutic window and minimizing off-target effects.

• Identifying specific metabolic vulnerabilities in different cancer types and patient populations is essential for successful targeted therapy.